CDIO Company Profile and Key Details

CDIO has shown weak momentum, losing -9.79% over the past week and -59.16% over the past quarter, though year-to-date performance is down -35.42%. Short-term trend indicators are bullishly aligned (SMA20 152.42%, SMA50 122.77%, SMA200 47.79%). The stock’s 14-day RSI is 84.42 (overbought), while the ATR of 0.62 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -69.98% below its high and over 438.14% above its low. Average 10-day trading volume of 29.97 thousand shares is below the 3-month average of 3.81 million, indicating normal recent market interest.

Cardio Diagnostics Holdings, Inc. has 1.76 million shares outstanding. The public float is 1.63 million shares, elevated short interest at 1.05% of float. This equals 17.25 thousand shares. The short ratio is 0.51 days. Institutional investors hold 5.18% of the float. Insiders own 7.16%. Philibert Robert holds 1.68 million shares, Dogan Meeshanthini has 1.66 million shares and Dogan Timur has 197.31 thousand shares.

The latest quarter delivered EPS of -$0.80. The next quarter is forecast at $nan. Next year's EPS is expected at $8.75. Cardio Diagnostics Holdings, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended March 13, 2026, missed forecasts by -55.56%. The prior quarter beat by -45.56%. Over the last six quarters, Apple has recorded several small beats. These include -60.0% in November 13, 2024.

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) closed at $1.88 USD, gaining $0.09 (5.03%) from the previous close of $1.79. The stock is currently mid-range between its 52-week high and low $0.97 and $14.46. With a market capitalization of about $3.48 million, Cardio Diagnostics Holdings, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.26). Key stats such as the average daily volume over the past year has been around 3.76 million shares, volume is running light vs its 52-week average. Headquartered in Chicago, IL, Cardio Diagnostics Holdings, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Meeshanthini V. Dogan, the company employs approximately 13 people and listed since January 14, 2022. Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease.

Cardio Diagnostics Holdings, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.00. This means the shares are trading below this model’s fair value.

Cardio Diagnostics Holdings, Inc. trades at a P/E ratio of -0.53, slightly below the S&P 500 average, with a price-to-sales ratio of 235.0 and a price-to-book ratio of 0.49 suggesting the stock is closer to book value. The P/FCF stands at -0.58, also below market averages.

Our AI price prediction model suggests that Cardio Diagnostics Holdings, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -34.08%, with price expected at $1.18 by May 14, 2026, within a range of $0.29 to $1.97 3-Month Outlook: Projected fall of -96.65%, reaching $0.06 by July 29, 2026, with a range of $0.00 to $0.60. 1-Year Outlook: Projected loss of -91.62%, with price at $0.15 by April 30, 2027, within a range of $0.00 to $1.61.

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) shares are down -35.42% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Cardio Diagnostics Holdings, Inc. trading at a premium to the broader market with a P/E of -0.53. Analyst sentiment is cautious, with the majority of ratings in Speculative Buy territory and a mean price target of $6.50, suggesting 263.13% upside. Our AI forecast model points to short-term weakness (-34.08% over two weeks), a medium-term fall (-96.65% over three months), and a longer-term loss (-91.62% over one year), with expected trading ranges indicating moderate volatility.